The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. — VialBase Research

Summary

This review evaluates LL-37 as a potential alternative to conventional antibiotics in the context of rising antimicrobial resistance, and is notable for being as explicit about the peptide’s failures as its promise. The authors note that LL-37 displays broad spectrum antibacterial and anti-biofilm activity as well as immunomodulatory functions, which is why it has been repeatedly proposed as a therapeutic candidate — and then state plainly that despite showing promising results, LL-37 has yet to receive regulatory approval as a peptide antibiotic. The stated reasons are concrete: high cost, lower activity in physiological environments, susceptibility to proteolytic degradation, and high toxicity to human cells. The review then examines a set of problems that get little attention in promotional writing about the peptide, namely antimicrobial resistance and cross-resistance to LL-37 itself, and adaptive bacterial responses to sub-inhibitory concentrations of the peptide — i.e. the possibility that exposing bacteria to less-than-killing doses of a host defense peptide drives adaptation. The remainder surveys possible workarounds: immobilization techniques, LL-37 delivery systems, development of LL-37 derivatives, and synergistic combinations with existing antibiotics, along with structural modifications to sequence, helicity, hydrophobicity, charge and configuration intended to optimize antimicrobial and anti-biofilm activity for future clinical use. The framing throughout is that these are challenges to be overcome before clinical viability, not solved problems.

Key Findings

• LL-37 has broad spectrum antibacterial and anti-biofilm activity plus immunomodulatory function, making it a candidate alternative to conventional antibiotics
• Despite promising results, LL-37 has not received regulatory approval as a peptide antibiotic
• Four named limitations block clinical translation: high cost, lower activity in physiological environments, susceptibility to proteolytic degradation, and high toxicity to human cells
• The review addresses antimicrobial resistance and cross-resistance to LL-37, and adaptive bacterial responses to sub-inhibitory concentrations of the peptide
• Proposed mitigations are all still developmental: immobilization techniques, delivery systems, LL-37 derivatives, synergistic antibiotic combinations, and structural modification of sequence, helicity, hydrophobicity, charge and configuration

Relevance to LL-37

This review is the corrective to the common framing of LL-37 as a natural, broadly safe antimicrobial. It confirms the impressive breadth of the peptide’s activity — broad spectrum antibacterial, anti-biofilm, immunomodulatory — while stating directly that LL-37 has not been approved as a peptide antibiotic and identifying high toxicity to human cells as one of the specific reasons, alongside high cost, reduced activity under physiological conditions, and proteolytic degradation. The point about lower activity in physiological environments is particularly relevant to anyone reading in vitro MIC data as if it predicted results in the body. The section on adaptive bacterial responses to sub-inhibitory concentrations also raises a real concern about casual, under-dosed use of a host defense peptide. Being a narrative review, it offers no efficacy or safety data of its own, but it is the single best source for why LL-37 remains a research compound rather than an approved drug.

Citation

Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel, Switzerland). 2021;10(6). doi:10.3390/antibiotics10060650.

See Also

• Parent compound: LL-37